ABSTRACT
Today in Nanomedicine? .......................................................................................... 525 23.1.3 Read the Literature ................................................................................................... 526 23.1.4 Early Commercialization and Access to a Wealth of Expertise: Just Ask Us .......... 527 23.1.5 This Chapter ............................................................................................................. 528
23.2 What We Knew in 1995 ........................................................................................................ 529 23.2.1 Doxorubicin and Liposomes ..................................................................................... 530
23.2.1.1 Doxorubicin, the Drug ............................................................................... 530 23.2.1.2 Doxorubicin Encapsulated in Liposomes .................................................. 532 23.2.1.3 New Toxicities for Doxil® .......................................................................... 535
23.2.2 Hyperthermia ............................................................................................................ 536 23.2.2.1 Effects of Hyperthermia ............................................................................ 537
23.2.3 Lipid Membrane Mechanochemistry ....................................................................... 538 23.2.3.1 Starting with Red Blood Cells ................................................................... 538 23.2.3.2 Giant Unilamellar Vesicle Experiments .................................................... 539
23.3 Engineering Design of the LTSL .......................................................................................... 547 23.3.1 Lysolipid Exchange with Membranes Generates the “Idea” ....................................548 23.3.2 Mechanism of Release ..............................................................................................548
23.4 Performance in Preclinical Studies ...................................................................................... 549 23.4.1 All 11/11 Mice Are “Cured” ..................................................................................... 549 23.4.2 Not All Cancers Respond the Same ......................................................................... 550 23.4.3 New Paradigm for Local Drug Delivery: Drug Release in the Bloodstream
